Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?

The aim of this review article is to make readers aware of the risk of an inadequate antiplatelet effect of enteric-coated formulations of aspirin. Judging by data from studies published to date and exploring the efficacy of various aspirin formulations, there exist sufficient evidences only of a plain form of aspirin absorbed in the stomach. The implication is that patients with coronary heart disease (CHD) should be treated exclusively with the standard formulation of aspirin.